Targeting Drug Resistance In HCV NS3/4A Protease: Mechanisms And Inhibitor Design Strategies
The Hepatitis C virus (HCV) NS3/4A protease inhibitors (PIs) have become a mainstay of newer all-oral combination therapies. Despite improvements in potency of this inhibitor class, drug resistance remains a problem with the rapid emergence of resistance-associated substitutions (RASs). In this thes...
Main Author: | |
---|---|
Format: | Others |
Published: |
eScholarship@UMMS
2018
|
Subjects: | |
Online Access: | https://escholarship.umassmed.edu/gsbs_diss/969 https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1975&context=gsbs_diss |